MedTrace Logo

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

NCT05942963 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-07-12

No results posted yet for this study

Summary

This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM. Study participants will be asked to fill out a few questions on proforma that will obtain demographic information as well as information relating to their health. In addition, some blood tests will be done following standard procedures.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Type2diabetes

Interventions

DRUG

Empagliflozin 10 MG

10-25 mg/day

DRUG

Pioglitazone 15mg

15-45 mg/day

DRUG

Metformin

1000mg-2850mg/ day

Sponsors & Collaborators

  • Jinnah Postgraduate Medical Centre

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05942963 on ClinicalTrials.gov